Amicus Therapeutics (NASDAQ: FOLD) reported Q2 EPS of ($0.34), versus ($0.40) reported last year. Revenue for the quarter came in at $7.2 million, versus $4.2 million reported last year.

• 179 Fabry Disease Patients on Reimbursed Galafold (migalastat) as of July 31 – On Target to Reach 300 Patients by Year-End 2017
• Migalastat NDA Submission Targeted for 4Q17
• Phase 3 EB Topline Data and Complete Phase 1/2 Pompe Data on Track for Late 3Q17

John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, stated, “During the second quarter and into the third quarter we have continued to successfully execute across all five of our strategic priorities which include the international launch for our oral precision medicine Galafold (migalastat) for Fabry disease, the advancement of our lead clinical programs in Epidermolysis Bullosa and Pompe disease, and further strengthening of our balance sheet. Our progress during the first half of this year has been driven by our focused execution and groundbreaking science which is tremendous for patients as well as our shareholders. We have created a solid foundation to continue building on this momentum as we approach several important milestones in the second half of this year. I believe that today, more than ever before, Amicus is well-positioned to become a leading global biotechnology company with the potential to deliver significant benefits to people living with rare devastating diseases.”

2017 Financial Guidance

Cash, cash equivalents, and marketable securities totaled $227.2 million at June 30, 2017 compared to $330.4 million at December 31, 2016. The Company added to the quarter-ending cash position with $243.2 million in net proceeds from a follow on public offering in July 2017.

Amicus continues to expect full-year 2017 net operating cash spend of between $175 million to $200 million and full-year 2017 total net cash spend (including third-party milestone payments and capital expenditures) of between $200 million and $225 million. The current cash position, in addition to the net proceeds of $243.2 million from the follow-on public offering, is anticipated to fund ongoing operations into at least the second half of 2019.

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.